Synpromics Promoter Technology Moves Closer to the Clinic

Synpromics announces positive data presented today by uniQure at the European Society of Gene and Cell Therapy conference. The study used uniQure’s next-generation liver-directed gene therapy system that incorporates a short, highly-selective and powerful liver promoter that was developed by Synpromics.

Excellent science, attracting global talent and investment, creating jobs, growth and delivering the therapies of the future – the state of the UK bioscience ecosystem in 2018

Commenting on the state of the UK life sciences ecosystem in a keynote address to the Bioindustry Association (BIA) UK Bioscience Forum in London BIA CEO Steve Bates OBE, will say: “The UK life sciences ecosystem is in a fantastic place. I see innovation, opportunity and collaboration everywhere. We are in an era of profound scientific opportunity.” The opening address will cover key issues that are currently having an impact on the UK bioscience ecosystem including government funding, Brexit, R&D development, the NHS and the future of the European Medicines Agency (EMA).

Blue Earth Diagnostics wins prestigious “Best Emerging Biotech” award

Oxford, UK – October 12, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, has won the Oxford Bio Network (OBN) award for “Best Emerging Biotech ”. These prestigious OBN awards, which are judged by a panel of leading industry entrepreneurs and experts, celebrate innovation and outstanding achievement across the UK’s Life Sciences industry.

Synpromics Unveils Next Generation Liver Selective and Tunable Promoter Platform

Synpromics is today unveiling its novel drug-regulatable promoter platform at the European Society of Cell and Gene Therapy (ESGCT) congress in Lausanne, Switzerland. The company is showcasing data generated from its innovative liver selective inducible and repressible synthetic promoter systems that are tightly controlled by FDA-approved small molecule drugs.

BIA launches videos and explainer documents celebrating UK bioscience and revealing the cutting-edge R&D taking place in biotech companies around the UK

The UK BioIndustry Association (BIA) has today launched a series of four explainer booklets and five videos that celebrate the fantastic work taking place in UK bioscience companies to create innovative new drugs and treatments for patients.

Life Sciences Industrial Strategy & Sector Deal Newsletter | October 2018

Welcome to the October edition of the Life Sciences Industrial Strategy & Sector Deal Newsletter. Here you will find an update on how we are progressing with the implementation of phase 1 of the Life Sciences Sector Deal as well as our upcoming priorities and engagement opportunities.

CEO Update | Monday 15 October 2018

We’re at the beginning of a  key week for the BIA as voting closes for our Board elections, and Thursday sees our flagship conference, the Bioscience Forum, along with our AGM and Autumn reception.

Evonetix named Best Synthetic Biology Company at OBN Awards

CAMBRIDGE, UK, 12 October 2018 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to scalable and high-fidelity gene synthesis, has received the award for “Best Emerging Synthetic Biology Company” at the 10th Anniversary of the Oxford Bioscience Network (OBN) Awards, in recognition of the Company’s novel gene synthesis technology, and its potential to facilitate the rapidly growing field of synthetic biology.

Evonetix wins Best Emerging Synthetic Biology Company at the OBN Awards

SynbiCITE would like to congratulate Evonetix on winning ‘Best Emerging Synthetic Biology Company’ at the 10th Annual OBN Awards Ceremony last night. The award recognises the emerging UK industrial or synthetic biology company that demonstrates the most promise. Entrants were assessed on capital raised, level of innovation and their contribution to the bioeconomy.